Intercellular adhesion molecule inhibitors as potential therapy for refractory uveitic macular edema

Ocular Immunology and Inflammation

Volumn 18, Issue 5, 2010, Pages 395-398

  Wang, Jianmin ^a,b   Ibrahim, Mohamed ^b   Turkcuoglu, Peykan ^a,c   Hatef, Elham ^a   Khwaja, Afsheen ^a   Channa, Roomasa ^a   Do, Diana V ^a   Nguyen, Quan Dong ^a  

^a JOHNS HOPKINS UNIVERSITY   (United States)

^b HEBEI MEDICAL UNIVERSITY   (China)

^c INONU UNIVERSITY SCHOOL OF MEDICINE   (Turkey)

Author keywords

ICAM inhibitor; Macular edema; Uveitis

Indexed keywords

CORTICOSTEROID; EFALIZUMAB; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; RHEUMATOID FACTOR; TRIAMCINOLONE ACETONIDE;

ADULT; AFRICAN AMERICAN; AMNESIA; ARTICLE; AUTOIMMUNE DISEASE; CASE REPORT; CORTICOSTEROID THERAPY; DRUG TOLERABILITY; FLUORESCENCE ANGIOGRAPHY; HIP PAIN; HUMAN; IDIOPATHIC DISEASE; IMMUNOMODULATION; IMMUNOTHERAPY; MALE; MOTOR DYSFUNCTION; MUSCLE TWITCH; NUCLEAR MAGNETIC RESONANCE IMAGING; OPHTHALMOSCOPY; OPTICAL COHERENCE TOMOGRAPHY; ORBIT DISEASE; RETINA MACULA EDEMA; SIDE EFFECT; SLIT LAMP; SYSTEMIC THERAPY; TREATMENT DURATION; TREATMENT OUTCOME; UVEITIS; VISUAL ACUITY;

ANTIBODIES, MONOCLONAL; AUTOIMMUNE DISEASES; CELL ADHESION MOLECULES; HUMANS; INJECTIONS, SUBCUTANEOUS; MACULAR EDEMA; MALE; MIDDLE AGED; TOMOGRAPHY, OPTICAL COHERENCE; TREATMENT OUTCOME; UVEITIS, POSTERIOR;

EID: 77956828128     PISSN: 09273948     EISSN: 17445078     Source Type: Journal    
DOI: 10.3109/09273948.2010.483317     Document Type: Article

References (12)

1. Cordero Coma M, Sobrin L, Onal S, et al. Intravitreal bevacizumab for the treatment of uveitic macular edema. Ophthalmology. 2007; 114: 1574-1579.
2. Okhravi N, Lightman S. Cystoid macular edema in uveitis. Ocul Immunol Inflamm. 2003; 11: 29-38.
3. Jois S.D.S, Jining L, Nagarajarao LM. Targeting T-cell adhesion molecules for drug design. Curr Pharm Des. 2006; 12: 2797-2812.
4. Frank PG, Lisanti MP. ICAM-1: role in inflammation and in the regulation of vascular permeability. Am J Physiol Heart Circ Physiol. 2008; 295: H926-H927.
5. Klok AM, Luyendijk L, Zaal MJW, et al. Soluble ICAM-1 serum levels in patients with intermediate uvietis. Br J Ophthal. 1999; 83: 847-851.
6. Sijssens KM, Rijkers GT, Rothova A, et al. Cytokines, chemokines and soluble adhesion molecules in aqueous homor of children with uveitis. Exp Eye Res. 2007; 85: 443-449.
7. Sumagin R, Lomakina E, Sarelius IH. Leukocyte-endothelial cell interactions are linked to vascular permeability via ICAM-1-mediated signaling. Am J Physiol Heart Circ Physiol. 2008; 295: H969-H977.
8. Funatsu H, Noma H, Mimura T, et al. Association of vitreous inflammatory factors with diabetic macular edema. Ophthalmology. 2009; 116: 73-79.
9. Li S, Wang H, Peng BZ, Zhang M, et al. Efalizumab binding to the LFA-1 αL| domain blocks ICAM-1 binding via steric hindrance. Proc Natl Acad Sci U S A. 2009; 106: 4349-4354.
10. Whitcup SM, DeBarge LR, Caspi RR, et al. Monoclonal antibodies against ICAM-1 (CD54) and LFA-1 (CD11a/CD18) inhibit experimental autoimmune uveitis. Clin Immunol Immunopathol. 1993; 67: 143-150.
11. UchioE, Kijima M, Tanaka S, et al. Suppression of experimental uveitis with monoclonal antibodies to ICAM-1 and LFA-1. Invest Ophthalmol Vis Sci. 1994; 35: 2626-2631.
12. Gahmberg CG. Leukocyte adhesion: CD11/CD18 integrins and intercellular adhesion molecules. Curr Opin Cell Biol. 1997; 9: 643-650.